Hereditary Angioedema (HAE) - Pipeline Review, H2 2014

Date: November 18, 2014
Pages: 77
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H06E3164BF7EN
Leaflet:

Download PDF Leaflet

Hereditary Angioedema (HAE) - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Hereditary Angioedema (HAE) - Pipeline Review, H2 2014’, provides an overview of the Hereditary Angioedema (HAE)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hereditary Angioedema (HAE) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hereditary Angioedema (HAE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hereditary Angioedema (HAE) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Hereditary Angioedema (HAE) Overview
Therapeutics Development
Pipeline Products for Hereditary Angioedema (HAE) - Overview
Pipeline Products for Hereditary Angioedema (HAE) - Comparative Analysis
Hereditary Angioedema (HAE) - Therapeutics under Development by Companies
Hereditary Angioedema (HAE) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hereditary Angioedema (HAE) - Products under Development by Companies
Hereditary Angioedema (HAE) - Companies Involved in Therapeutics Development
BioCryst Pharmaceuticals, Inc.
Cevec Pharmaceuticals GmbH
CSL Limited
Dyax Corp.
Global Blood Therapeutics, Inc.
iBio, Inc.
Isis Pharmaceuticals, Inc.
Pharming Group N.V.
Ra Pharmaceuticals, Inc.
Shire Plc
Hereditary Angioedema (HAE) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BCX-4161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BEL-0215 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CSL-3F7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclomimetic - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DX-2930 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
icatibant acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-PKKRx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Inhibit Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule 1 to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule 2 to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Hereditary Angioedema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hereditary Angioedema (HAE) - Recent Pipeline Updates
Hereditary Angioedema (HAE) - Dormant Projects
Hereditary Angioedema (HAE) - Product Development Milestones
Featured News & Press Releases
Nov 04, 2014: Pharming Confirms Receipt Of US$20 Million Milestone Payment From Salix Pharmaceuticals
Nov 03, 2014: Salix and Pharming Announce the Launch of RUCONEST in the U.S. for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Nov 03, 2014: Dyax Announces Expansion of Phase 1b Clinical Trial for DX-2930
Oct 13, 2014: Pharming and Swedish Orphan Biovitrum Amend and Extend Ruconest Distribution Agreement
Oct 07, 2014: BioCryst Announces Late Breaker Presentation of OPuS-1 Phase 2 Trial Results at the 23rd EADV Congress
Sep 15, 2014: Dyax Announces Issuance of Two Key U.S. Patents for DX-2930
Aug 28, 2014: Pharming and Salix Announce Initiation of Clinical Study of RUCONEST for Prophylaxis of Hereditary Angioedema
Jul 30, 2014: Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant
Jul 23, 2014: Dyax Corp. Announces Publication of Scientific Data for DX-2930 in Peer-Reviewed Journals
Jul 17, 2014: Salix and Pharming Announce FDA Approval of RUCONEST for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Hereditary Angioedema (HAE), H2 2014
Number of Products under Development for Hereditary Angioedema (HAE) - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Hereditary Angioedema (HAE) - Pipeline by BioCryst Pharmaceuticals, Inc., H2 2014
Hereditary Angioedema (HAE) - Pipeline by Cevec Pharmaceuticals GmbH, H2 2014
Hereditary Angioedema (HAE) - Pipeline by CSL Limited, H2 2014
Hereditary Angioedema (HAE) - Pipeline by Dyax Corp., H2 2014
Hereditary Angioedema (HAE) - Pipeline by Global Blood Therapeutics, Inc., H2 2014
Hereditary Angioedema (HAE) - Pipeline by iBio, Inc., H2 2014
Hereditary Angioedema (HAE) - Pipeline by Isis Pharmaceuticals, Inc., H2 2014
Hereditary Angioedema (HAE) - Pipeline by Pharming Group N.V., H2 2014
Hereditary Angioedema (HAE) - Pipeline by Ra Pharmaceuticals, Inc., H2 2014
Hereditary Angioedema (HAE) - Pipeline by Shire Plc, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Hereditary Angioedema (HAE) Therapeutics - Recent Pipeline Updates, H2 2014
Hereditary Angioedema (HAE) - Dormant Projects, H2 2014

LIST OF FIGURES

Number of Products under Development for Hereditary Angioedema (HAE), H2 2014
Number of Products under Development for Hereditary Angioedema (HAE) - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014

COMPANIES MENTIONED

BioCryst Pharmaceuticals, Inc.
Cevec Pharmaceuticals GmbH
CSL Limited
Dyax Corp.
Global Blood Therapeutics, Inc.
iBio, Inc.
Isis Pharmaceuticals, Inc.
Pharming Group N.V.
Ra Pharmaceuticals, Inc.
Shire Plc
Skip to top


Ask Your Question

Hereditary Angioedema (HAE) - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: